All In Biotech

Drug Trial Radar · NCT05331300

A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Preliminary Efficacy, Immunogenicity and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Jun 6, 2022

Primary completion

Nov 27, 2024

Study completion Nov 27, 2024

Sponsor

Lead sponsor
Lassen Therapeutics 1 PTY LTDIndustry
Sponsor type
Industry
First posted
Apr 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

LASN01 is a novel, fully human antibody directed against the human IL-11 receptor that is being developed to address the fibro-inflammatory pathology of pulmonary fibrosis and TED. This study is a four-part trial consisting of Parts A, B, C and D. The primary objective of this study is to evaluate the safety and tolerability of LASN01, and the secondary objective is to evaluate the preliminary efficacy, immunogenicity, and pharmacokinetics of single and multiple doses of LASN01 in healthy participants and in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrosing interstitial lung disease (PF-ILD) or Thyroid Eye disease (TED). Please note that both the Phase 1 (single and multiple ascending dose, SAD/MAD) portion in healthy volunteers and the Phase 2a portion in patients are completed.

Conditions

  • Pulmonary Fibrosis
  • Thyroid Eye Disease

Interventions

  • LASN01Drug

    Escalating single and multiple doses of LASN01

  • LASN01Drug

    LASN01 will be administered intravenously

  • PlaceboDrug

    Escalating doses of matching placebo

  • PlaceboDrug

    Placebo will be administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment emergent, treatment related, and serious adverse eventsTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D
  2. Changes in concomitant medicationsTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D
  3. Changes from Baseline in clinical laboratory evaluations following study drug administrationTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D
  4. Changes from Baseline in vital signs following study drug administrationTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D
  5. Changes from Baseline in 12-lead electrocardiogram (ECG) parameters following study drug administrationTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D
  6. Changes from Baseline in physical examination (PE) results following study drug administrationTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Site AU05

    Hurstville, New South Wales, Australia

  • Site AU03

    Brisbane, Queensland, Australia

  • Site AU01

    Melbourne, Victoria, Australia

  • Site HK01

    Shatin, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.